India news from FiercePharma
News
SPOTLIGHT: U.S. 'a complete mess,' Indian CEO says
Dr. Reddy's vice chair and CEO G.V. Prasad predicts increasing difficulty obtaining financing and declining market caps industry-wide as the U.S. economy slows. But, he says, India and China will Read more...
Could Clarinex be vulnerable to generics?
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
Teva abstains from Protonix fray
Teva Pharmaceuticals' dilemma: A rival generic drugmaker is ready Read more...
Can Novartis drug fill Gleevec's shoes?
It's a good-news, bad-news sort of day for Novartis' cancer drugs. First, the good news: Tasigna won European Union approval for treatment of chronic myeloid leukemia. A potential follow-up to Read more...
ALSO NOTED: Indian pharma set for 13 percent growth; Amgen pays for tax breaks on new warehouse;
> The Indian pharma industry is poised for 13 percent growth over the next three years, according to a new research report from Boston Analytics. Read more...
ALSO NOTED: Nexavar OK'd for use against liver cancer; Japan's Olympus to buy Gyrus in $1.9 billion deal;
> Bayer and Onyx Pharmaceuticals got the FDA's nod to market Nexavar to treat liver cancer; the drug already is used against kidney cancer. Read more...
ALSO NOTED: Diabetes-med use doubles in young girls; Ranbaxy settles patent fight with Astellas;
> Tween and teen girls drove a huge increase in type 2 diabetes prescriptions among kids. Report > India's Read more...
Glenmark to spin off generics business
India's Glenmark Pharmaceuticals plans to untie the apron strings by spinning off its generics business. Glenmark Generics, a wholly-owned subsidiary, will handle all the company's copycat drugs and Read more...
ALSO NOTED: GSK preps for India drug launches; Watson proceeds with challenge to Bayer drug;
> GlaxoSmithKline is preparing to launch its breast cancer drug Tykerb in India by early next year, with critical care and cardio drugs to follow. Read more...
Get more India coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight